- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01657643
Effect of Probiotics on Health-related Quality of Life in College Students With Upper Respiratory Infections
May 26, 2015 updated by: SHRP nutritional sciences, University of Medicine and Dentistry of New Jersey
Effect of Lactobacillus Rhamnosus LGG® and Bifidobacterium Animalis Ssp Lactis BB-12® on Health-related Quality of Life in College Students With Upper Respiratory Infections
The main purpose of the study is to find out if probiotics (healthy bacteria found in yogurt) can improve the health-related quality of life (HRQL) during upper respiratory infections (like the common cold) in college students living in residence hall on-campus at Framingham State University (Framingham, MA) who are randomized to receive a probiotic or placebo candy daily for 12 weeks.
HRQL is a subjective measure, defined as the aspects of quality of life (i.e., one's satisfaction with their life) that related specifically to a person's health (for example, ability to carry out normal daily activities).
The investigators hypothesize that HRQL during URIs will be significantly higher in the probiotic groups compared to the placebo group.
The proposed study will also seek to address the following secondary objectives: missed school and work days due to a upper respiratory infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
231
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Framingham, Massachusetts, United States, 01701
- Framingham State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 25 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Student at Framingham State University (Framingham, MA)
- Live in on-campus housing
Exclusion Criteria:
- their driver's license or state identification card indicated that they were under 18 years of age or over 25 years of age;
- they experienced chronic perennial allergies (such as, allergies to dust or 3) they were pregnant
4) they had been diagnosed with medical conditions affecting immune function (for example, asthma, chronic fatigue syndrome and human immunodeficiency virus) 5) they had acute pancreatitis, were undergoing treatment for cancer; or, were taking immunosuppressive drugs for an autoimmune disease or post-transplant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
|
|
EXPERIMENTAL: Probiotics
Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related quality of life
Time Frame: 12 weeks
|
Subjects are asked to complete a questionnaire every day for 12 weeks that inquires about any common cold symptoms that they may be experiencing, severity of the symptoms, and how the symptoms interfere with their daily activities.
Health-related quality of life is operationalized by total score on the questionnaire.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Missed work days
Time Frame: Once per week over the course of 12 weeks
|
Once per week, for 12 weeks, subjects are asked to complete a questionnaire that inquires about missed work days.
|
Once per week over the course of 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Missed school days
Time Frame: Once per week over the course of 12 weeks
|
Once per week, for 12 weeks, subjects are asked to complete a questionnaire that inquires about missed school days.
|
Once per week over the course of 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tracey J Smith, PhD, University of Medicine and Dentistry of New Jersey
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (ACTUAL)
May 1, 2011
Study Completion (ACTUAL)
May 1, 2011
Study Registration Dates
First Submitted
July 28, 2012
First Submitted That Met QC Criteria
August 3, 2012
First Posted (ESTIMATE)
August 6, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
May 28, 2015
Last Update Submitted That Met QC Criteria
May 26, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0120100395
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Respiratory Infection
-
NovartisNovartis Consumer HealthCompleted
-
Daewon Pharmaceutical Co., Ltd.CompletedFever | Acute Upper Respiratory InfectionKorea, Republic of
-
China Academy of Chinese Medical SciencesGuangdong Provincial Hospital of Traditional Chinese Medicine; Guang'anmen... and other collaboratorsUnknownAcute Upper Respiratory InfectionChina
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedAcute Upper Respiratory InfectionChina
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedAcute Upper Respiratory InfectionChina
-
Société des Produits Nestlé (SPN)Completed
-
Hanmi Pharmaceutical Company LimitedUnknownAcute Upper Respiratory Infection | Acute BronchitisKorea, Republic of
-
University of California, San FranciscoVapore, LLCWithdrawnAcute Upper Respiratory Infection | Signs and SymptomsUnited States
-
Altesa Biosciences, Inc.Virtus Respiratory ResearchRecruitingRCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionInfections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditionsUnited Kingdom
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States